Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects.

Rubino CM, Bhavnani SM, Loutit JS, Morgan EE, White D, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02228-17. doi: 10.1128/AAC.02228-17. Print 2018 Apr.

2.

Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.

Rubino CM, Bhavnani SM, Loutit JS, Lohse B, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02103-17. doi: 10.1128/AAC.02103-17. Print 2018 Mar.

3.

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects.

Griffith DC, Loutit JS, Morgan EE, Durso S, Dudley MN.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6326-32. doi: 10.1128/AAC.00568-16. Print 2016 Oct.

4.

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.

Flume PA, VanDevanter DR, Morgan EE, Dudley MN, Loutit JS, Bell SC, Kerem E, Fischer R, Smyth AR, Aaron SD, Conrad D, Geller DE, Elborn JS.

J Cyst Fibros. 2016 Jul;15(4):495-502. doi: 10.1016/j.jcf.2015.12.004. Epub 2016 Feb 4.

5.

Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects.

Wenzler E, Gotfried MH, Loutit JS, Durso S, Griffith DC, Dudley MN, Rodvold KA.

Antimicrob Agents Chemother. 2015 Dec;59(12):7232-9. doi: 10.1128/AAC.01713-15. Epub 2015 Sep 8.

6.

Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.

Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, King P, Tsivkovski R, Sun D, Sabet M, Tarazi Z, Clifton MC, Atkins K, Raymond A, Potts KT, Abendroth J, Boyer SH, Loutit JS, Morgan EE, Durso S, Dudley MN.

J Med Chem. 2015 May 14;58(9):3682-92. doi: 10.1021/acs.jmedchem.5b00127. Epub 2015 Mar 17.

PMID:
25782055
7.

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.

Stuart Elborn J, Geller DE, Conrad D, Aaron SD, Smyth AR, Fischer R, Kerem E, Bell SC, Loutit JS, Dudley MN, Morgan EE, VanDevanter DR, Flume PA.

J Cyst Fibros. 2015 Jul;14(4):507-14. doi: 10.1016/j.jcf.2014.12.013. Epub 2015 Jan 13.

8.

Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa.

Geller DE, Flume PA, Staab D, Fischer R, Loutit JS, Conrad DJ; Mpex 204 Study Group.

Am J Respir Crit Care Med. 2011 Jun 1;183(11):1510-6. doi: 10.1164/rccm.201008-1293OC. Epub 2011 Feb 25.

PMID:
21471106
9.

Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects.

Geller DE, Flume PA, Griffith DC, Morgan E, White D, Loutit JS, Dudley MN.

Antimicrob Agents Chemother. 2011 Jun;55(6):2636-40. doi: 10.1128/AAC.01744-10. Epub 2011 Mar 28.

10.

Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults.

Rubino CM, Bhavnani SM, Ambrose PG, Forrest A, Loutit JS.

Pulm Pharmacol Ther. 2009 Aug;22(4):279-85. doi: 10.1016/j.pupt.2009.03.003. Epub 2009 Mar 27.

PMID:
19328861
11.

Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia.

Bhavnani SM, Passarell JA, Owen JS, Loutit JS, Porter SB, Ambrose PG.

Antimicrob Agents Chemother. 2006 Mar;50(3):994-1000.

12.

Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose.

Fetterly GJ, Ong CM, Bhavnani SM, Loutit JS, Porter SB, Morello LG, Ambrose PG, Nicolau DP.

Antimicrob Agents Chemother. 2005 Jan;49(1):148-52.

13.

Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects.

Bhavnani SM, Owen JS, Loutit JS, Porter SB, Ambrose PG.

Diagn Microbiol Infect Dis. 2004 Oct;50(2):95-102.

PMID:
15474317
14.

Pneumocephalus due to invasive fungal sinusitis.

Engel G, Fearon WF, Kosek JC, Loutit JS.

Clin Infect Dis. 2000 Jan;30(1):215-7. No abstract available.

PMID:
10619764
15.

Bartonella infections: diverse and elusive.

Loutit JS.

Hosp Pract (1995). 1998 Dec 15;33(12):37-8, 41-4, 49.

PMID:
9866646
16.

Lemierre's syndrome.

Lee BK, Lopez F, Genovese M, Loutit JS.

South Med J. 1997 Jun;90(6):640-3.

PMID:
9191743
17.

Bartonella infections.

Loutit JS.

Curr Clin Top Infect Dis. 1997;17:269-90. Review. No abstract available.

PMID:
9189670
18.

Bartonella henselae and Bartonella quintana adherence to and entry into cultured human epithelial cells.

Batterman HJ, Peek JA, Loutit JS, Falkow S, Tompkins LS.

Infect Immun. 1995 Nov;63(11):4553-6.

20.

The agent of bacillary angiomatosis. An approach to the identification of uncultured pathogens.

Relman DA, Loutit JS, Schmidt TM, Falkow S, Tompkins LS.

N Engl J Med. 1990 Dec 6;323(23):1573-80.

21.

Isolation of multiple mutants of Pseudomonas aeruginosa capable of efficient thymine salvage.

Potter AA, Loutit JS.

Can J Genet Cytol. 1983 Oct;25(5):518-23.

PMID:
6418363
22.

FP2 plasmid curing in Pseudomonas aeruginosa.

Potter AA, Loutit JS.

Can J Microbiol. 1983 Jun;29(6):732-3.

PMID:
6411318
23.
24.

Thymine metabolism in Pseudomonas aeruginosa strain 1: the presence of a salvage pathway.

Potter AA, Musgrave DR, Loutit JS.

J Gen Microbiol. 1982 Jul;128(7):1391-400.

PMID:
6811694
25.
26.

The replication of the chromosome of Pseudomonas aeruginosa strain 1. II. Sequential mutagenesis of synchronized cultures.

Booker RJ, Loutit JS.

Genet Res. 1975 Jun;25(3):215-28. No abstract available.

PMID:
810389
27.
28.

Mutants of Pseudomonas aeruginosa strain 1 with unusual acetohydroxy acid synthetase enzymes.

Loutit JS, Davis PF.

Biochim Biophys Acta. 1970 Oct 27;222(1):222-5. No abstract available.

PMID:
4990804
29.
30.
31.
33.

Identification of aerobic heterotrophic soil bacteria to generic level by using multipoint inoculation techniques.

Bowie IS, Loutit MW, Loutit JS.

Can J Microbiol. 1969 Mar;15(3):297-302. No abstract available.

PMID:
4181135
34.

Investigation of the mating system of Pseudomonas aeruginosa strain 1. IV. Mapping of distal markers.

Loutit JS.

Genet Res. 1969 Feb;13(1):91-8. No abstract available.

PMID:
4977062
35.

Investigation of the mating system of Pseudomonas aeruginosa strain 1. 3. Kinetic studies on the transfer of the sex factor (FP).

Loutit JS, Marinus MG, Pearce LE.

Genet Res. 1968 Oct;12(2):139-45. No abstract available.

PMID:
4974341
36.

Investigation of the mating system of Pseudomonas aeruginosa strain 1. II. Mapping of a number of early markers.

Loutit JS, Marinus MG.

Genet Res. 1968 Aug;12(1):37-44. No abstract available.

PMID:
4976997
37.

Investigation of the mating system of Pseudomonas aeruginosa strain 1. I. Kinetic studies.

Loutit JS, Pearce LE, Marinus MG.

Genet Res. 1968 Aug;12(1):29-36. No abstract available.

PMID:
4976996
38.

KINETICS OF MATING OF FP+ AND FP- STRAINS OF PSEUDOMONAS AERUGINOSA.

LOUTIT JS, PEARCE LE.

J Bacteriol. 1965 Aug;90:425-30.

39.

MATING IN PSEUDOMONAS AERUGINOSA.

LOUTIT JS, PEARCE LE.

Nature. 1965 Feb 20;205:822. No abstract available.

PMID:
14293152
40.
41.
42.

Effect of ultra-violet irradiation on transduction in Pseudomonas aerginosa.

LOUTIT JS.

Nature. 1959 Dec 19;184(Suppl 25):1960-1. No abstract available.

PMID:
14418452
43.

A transduction-like process within a single strain of Pseudomonas aeruginosa.

LOUTIT JS.

J Gen Microbiol. 1958 Apr;18(2):315-9. No abstract available.

PMID:
13525650
44.

Auxotrophic mutants of Pseudomonas aeruginosa.

LOUTIT JS.

Nature. 1955 Jul 9;176(4471):74-5. No abstract available.

PMID:
13244618
45.

Supplemental Content

Loading ...
Support Center